FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989806579> ?p ?o ?g. }

• W2989806579 abstract "Nonalcoholic steatohepatitis (NASH) has become the most common cause of chronic liver disease worldwide in recent years. The pathogenesis of NASH is closely linked to metabolic diseases such as insulin resistance, obesity, dyslipidemia, and type 2 diabetes. However, there is currently no pharmacological agent for preventing the progression of NASH. Sodium–glucose cotransporter (SGLT) 2 inhibitors increase urinary glucose excretion by inhibiting renal glucose reabsorption, and improve various pathological conditions of type 2 diabetes, including insulin resistance. In the present study, we examined the effects of ipragliflozin, a SGLT2-selective inhibitor, alone and in combination with pioglitazone on NASH in high-fat diet-fed KK/Ay type 2 diabetic mice. Type 2 diabetic mice with NASH exhibited steatosis, inflammation, and fibrosis in the liver as well as hyperglycemia, insulin resistance, and obesity, features that are observed in human NASH. Four-week repeated administration of ipragliflozin (0.1–3 mg/kg) led to significant improvements in hyperglycemia, insulin resistance, and obesity in addition to hyperlipidemia and liver injury including hepatic steatosis and fibrosis. Moreover, ipragliflozin reduced inflammation and oxidative stress in the liver. Repeated administration of pioglitazone (3–30 mg/kg) also significantly improved various parameters of diabetes and NASH, excluding obesity. Furthermore, combined treatment comprising ipragliflozin (1 mg/kg) and pioglitazone (10 mg/kg) additively improved these parameters. These findings indicate that the SGLT2-selective inhibitor ipragliflozin improves hyperglycemia as well as NASH in type 2 diabetic mice. Therefore, treatment with ipragliflozin monotherapy or coadministered with pioglitazone is expected to be a potential therapeutic option for the treatment of type 2 diabetes with NASH." @default.
• W2989806579 created "2019-12-05" @default.
• W2989806579 creator A5017481949 @default.
• W2989806579 creator A5080346888 @default.
• W2989806579 date "2019-11-01" @default.
• W2989806579 modified "2023-10-16" @default.
• W2989806579 title "SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model" @default.
• W2989806579 cites W1523155649 @default.
• W2989806579 cites W1868475579 @default.
• W2989806579 cites W1965367230 @default.
• W2989806579 cites W1972011038 @default.
• W2989806579 cites W1976509021 @default.
• W2989806579 cites W1978666738 @default.
• W2989806579 cites W1987679510 @default.
• W2989806579 cites W1994845027 @default.
• W2989806579 cites W1995784269 @default.
• W2989806579 cites W1996482353 @default.
• W2989806579 cites W1998369233 @default.
• W2989806579 cites W2010220662 @default.
• W2989806579 cites W2016103822 @default.
• W2989806579 cites W2017849767 @default.
• W2989806579 cites W2020195767 @default.
• W2989806579 cites W2020949125 @default.
• W2989806579 cites W2024214508 @default.
• W2989806579 cites W2039068863 @default.
• W2989806579 cites W2061662539 @default.
• W2989806579 cites W2066088297 @default.
• W2989806579 cites W2069845056 @default.
• W2989806579 cites W2072838075 @default.
• W2989806579 cites W2072957141 @default.
• W2989806579 cites W2074154145 @default.
• W2989806579 cites W2074203821 @default.
• W2989806579 cites W2079454650 @default.
• W2989806579 cites W2083685463 @default.
• W2989806579 cites W2084793391 @default.
• W2989806579 cites W2095574383 @default.
• W2989806579 cites W2105196519 @default.
• W2989806579 cites W2107943478 @default.
• W2989806579 cites W2123984464 @default.
• W2989806579 cites W2125946144 @default.
• W2989806579 cites W2132866343 @default.
• W2989806579 cites W2133795831 @default.
• W2989806579 cites W2150640537 @default.
• W2989806579 cites W2151713218 @default.
• W2989806579 cites W2159773554 @default.
• W2989806579 cites W2161311866 @default.
• W2989806579 cites W2164118055 @default.
• W2989806579 cites W2186318742 @default.
• W2989806579 cites W2287058651 @default.
• W2989806579 cites W2299455978 @default.
• W2989806579 cites W2341165197 @default.
• W2989806579 cites W2398592169 @default.
• W2989806579 cites W2469884964 @default.
• W2989806579 cites W2561077285 @default.
• W2989806579 cites W2577902252 @default.
• W2989806579 cites W2613375469 @default.
• W2989806579 cites W2730267177 @default.
• W2989806579 cites W2742155329 @default.
• W2989806579 cites W2743468233 @default.
• W2989806579 cites W2775026689 @default.
• W2989806579 cites W2808987855 @default.
• W2989806579 cites W2811102551 @default.
• W2989806579 cites W2914961474 @default.
• W2989806579 cites W2961666778 @default.
• W2989806579 cites W2970792496 @default.
• W2989806579 cites W2989806579 @default.
• W2989806579 cites W4244511135 @default.
• W2989806579 cites W98196760 @default.
• W2989806579 doi "https://doi.org/10.14814/phy2.14286" @default.
• W2989806579 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6883099" @default.
• W2989806579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31782258" @default.
• W2989806579 hasPublicationYear "2019" @default.
• W2989806579 type Work @default.
• W2989806579 sameAs 2989806579 @default.
• W2989806579 citedByCount "17" @default.
• W2989806579 countsByYear W29898065792019 @default.
• W2989806579 countsByYear W29898065792020 @default.
• W2989806579 countsByYear W29898065792021 @default.
• W2989806579 countsByYear W29898065792022 @default.
• W2989806579 countsByYear W29898065792023 @default.
• W2989806579 crossrefType "journal-article" @default.
• W2989806579 hasAuthorship W2989806579A5017481949 @default.
• W2989806579 hasAuthorship W2989806579A5080346888 @default.
• W2989806579 hasBestOaLocation W29898065791 @default.
• W2989806579 hasConcept C126322002 @default.
• W2989806579 hasConcept C134018914 @default.
• W2989806579 hasConcept C2776175330 @default.
• W2989806579 hasConcept C2776954865 @default.
• W2989806579 hasConcept C2777180221 @default.
• W2989806579 hasConcept C2777391703 @default.
• W2989806579 hasConcept C2778384471 @default.
• W2989806579 hasConcept C2778772119 @default.
• W2989806579 hasConcept C2779134260 @default.
• W2989806579 hasConcept C2779478299 @default.
• W2989806579 hasConcept C555293320 @default.
• W2989806579 hasConcept C71924100 @default.
• W2989806579 hasConcept C90466245 @default.
• W2989806579 hasConcept C98274493 @default.
• W2989806579 hasConceptScore W2989806579C126322002 @default.
• W2989806579 hasConceptScore W2989806579C134018914 @default.

• next